These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34919011)

  • 41. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.
    van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M
    J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse outcome pathway from activation of the AhR to breast cancer-related death.
    Benoit L; Jornod F; Zgheib E; Tomkiewicz C; Koual M; Coustillet T; Barouki R; Audouze K; Vinken M; Coumoul X
    Environ Int; 2022 Jul; 165():107323. PubMed ID: 35660951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
    Sachana M; Willett C; Pistollato F; Bal-Price A
    Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?
    Coady K; Browne P; Embry M; Hill T; Leinala E; Steeger T; Maślankiewicz L; Hutchinson T
    Integr Environ Assess Manag; 2019 Jul; 15(4):633-647. PubMed ID: 30908812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a putative adverse outcome pathway network for male rat reproductive tract abnormalities with specific considerations for the androgen sensitive window of development.
    Palermo CM; Foreman JE; Wikoff DS; Lea I
    Curr Res Toxicol; 2021; 2():254-271. PubMed ID: 34401750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An integrative data-centric approach to derivation and characterization of an adverse outcome pathway network for cadmium-induced toxicity.
    Sahoo AK; Chivukula N; Ramesh K; Singha J; Marigoudar SR; Sharma KV; Samal A
    Sci Total Environ; 2024 Apr; 920():170968. PubMed ID: 38367714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.
    Vinken M; Landesmann B; Goumenou M; Vinken S; Shah I; Jaeschke H; Willett C; Whelan M; Rogiers V
    Toxicol Sci; 2013 Nov; 136(1):97-106. PubMed ID: 23945500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429).
    Tsamou M; Roggen EL
    J Alzheimers Dis Rep; 2022; 6(1):271-296. PubMed ID: 35891639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Developmental biology meets toxicology: contributing reproductive mechanisms to build adverse outcome pathways.
    Draskau MK; Spiller CM; Boberg J; Bowles J; Svingen T
    Mol Hum Reprod; 2020 Feb; 26(2):111-116. PubMed ID: 31943113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An integrative systems biology strategy to support the development of adverse outcome pathways (AOPs): a case study on radiation-induced microcephaly.
    Jaylet T; Quintens R; Armant O; Audouze K
    Front Cell Dev Biol; 2023; 11():1197204. PubMed ID: 37427375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reactive Oxygen Species in the Adverse Outcome Pathway Framework: Toward Creation of Harmonized Consensus Key Events.
    Tanabe S; O'Brien J; Tollefsen KE; Kim Y; Chauhan V; Yauk C; Huliganga E; Rudel RA; Kay JE; Helm JS; Beaton D; Filipovska J; Sovadinova I; Garcia-Reyero N; Mally A; Poulsen SS; Delrue N; Fritsche E; Luettich K; La Rocca C; Yepiskoposyan H; Klose J; Danielsen PH; Esterhuizen M; Jacobsen NR; Vogel U; Gant TW; Choi I; FitzGerald R
    Front Toxicol; 2022; 4():887135. PubMed ID: 35875696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.
    Bajard L; Adamovsky O; Audouze K; Baken K; Barouki R; Beltman JB; Beronius A; Bonefeld-Jørgensen EC; Cano-Sancho G; de Baat ML; Di Tillio F; Fernández MF; FitzGerald RE; Gundacker C; Hernández AF; Hilscherova K; Karakitsios S; Kuchovska E; Long M; Luijten M; Majid S; Marx-Stoelting P; Mustieles V; Negi CK; Sarigiannis D; Scholz S; Sovadinova I; Stierum R; Tanabe S; Tollefsen KE; van den Brand AD; Vogs C; Wielsøe M; Wittwehr C; Blaha L
    Environ Res; 2023 Jan; 217():114650. PubMed ID: 36309218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantification of an Adverse Outcome Pathway Network by Bayesian Regression and Bayesian Network Modeling.
    Moe SJ; Wolf R; Xie L; Landis WG; Kotamäki N; Tollefsen KE
    Integr Environ Assess Manag; 2021 Jan; 17(1):147-164. PubMed ID: 32965776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse outcome pathways: opportunities, limitations and open questions.
    Leist M; Ghallab A; Graepel R; Marchan R; Hassan R; Bennekou SH; Limonciel A; Vinken M; Schildknecht S; Waldmann T; Danen E; van Ravenzwaay B; Kamp H; Gardner I; Godoy P; Bois FY; Braeuning A; Reif R; Oesch F; Drasdo D; Höhme S; Schwarz M; Hartung T; Braunbeck T; Beltman J; Vrieling H; Sanz F; Forsby A; Gadaleta D; Fisher C; Kelm J; Fluri D; Ecker G; Zdrazil B; Terron A; Jennings P; van der Burg B; Dooley S; Meijer AH; Willighagen E; Martens M; Evelo C; Mombelli E; Taboureau O; Mantovani A; Hardy B; Koch B; Escher S; van Thriel C; Cadenas C; Kroese D; van de Water B; Hengstler JG
    Arch Toxicol; 2017 Nov; 91(11):3477-3505. PubMed ID: 29051992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Organizing mechanism-related information on chemical interactions using a framework based on the aggregate exposure and adverse outcome pathways.
    Price PS; Jarabek AM; Burgoon LD
    Environ Int; 2020 May; 138():105673. PubMed ID: 32217427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Case Study Application of the Aggregate Exposure Pathway (AEP) and Adverse Outcome Pathway (AOP) Frameworks to Facilitate the Integration of Human Health and Ecological End Points for Cumulative Risk Assessment (CRA).
    Hines DE; Edwards SW; Conolly RB; Jarabek AM
    Environ Sci Technol; 2018 Jan; 52(2):839-849. PubMed ID: 29236470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Harvesting the promise of AOPs: An assessment and recommendations.
    Carusi A; Davies MR; De Grandis G; Escher BI; Hodges G; Leung KMY; Whelan M; Willett C; Ankley GT
    Sci Total Environ; 2018 Jul; 628-629():1542-1556. PubMed ID: 30045572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. AOP Report: Glutathione Conjugation Leading to Reproductive Dysfunction via Oxidative Stress.
    Vieira LR; Souza T; Farias DF
    Environ Toxicol Chem; 2023 Dec; 42(12):2519-2528. PubMed ID: 37849373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps.
    Jaylet T; Coustillet T; Smith NM; Viviani B; Lindeman B; Vergauwen L; Myhre O; Yarar N; Gostner JM; Monfort-Lanzas P; Jornod F; Holbech H; Coumoul X; Sarigiannis DA; Antczak P; Bal-Price A; Fritsche E; Kuchovska E; Stratidakis AK; Barouki R; Kim MJ; Taboureau O; Wojewodzic MW; Knapen D; Audouze K
    Front Toxicol; 2024; 6():1285768. PubMed ID: 38523647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.